Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib/Metformin/Valsartan - ARKAY Therapeutics

Next Previous
Search
Drug Profile

Celecoxib/Metformin/Valsartan - ARKAY Therapeutics

Alternative Names: RK-01

Latest Information Update: 28 Apr 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARKAY Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Antihypertensives; Antirheumatics; Biguanides; Branched-chain amino acids; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Pyrazoles; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action AMP activated protein kinase stimulants; Angiotensin type 1 receptor antagonists; Cyclo-oxygenase 2 inhibitors; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 28 Apr 2022 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
  • 03 Oct 2018 The U.S. FDA approves IND application for the fixed dose combination of celecoxib/metformin/valsartan in Type-2 diabetes
  • 27 Sep 2018 ARKAY Therapeutics plans the phase I/II RESILIENCE trial for Type-2 diabetes mellitus (Newly diagnosed) in the US (NCT03686657)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top